| Abigail Debusk, DO | |
|
825 2nd Ave, Suite C2, Bowling Green, KY 42101-1786 | |
| (270) 780-2750 | |
| Not Available |
| Full Name | Abigail Debusk |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 825 2nd Ave, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154613768 | NPI | - | NPPES |
| 376962 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QS0010X | Family Medicine - Sports Medicine | 03735 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Commonwealth Health Corporation Inc | 5496667628 | 221 |
News Archive
Research from the University of Southampton has shown that young adults, who are more outgoing or more emotionally stable, are happier in later life than their more introverted or less emotionally stable peers.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There is no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV.
› Verified 5 days ago
| Entity Name | Prisma Health University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295763217 PECOS PAC ID: 8325950983 Enrollment ID: O20031103000238 |
News Archive
Research from the University of Southampton has shown that young adults, who are more outgoing or more emotionally stable, are happier in later life than their more introverted or less emotionally stable peers.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There is no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV.
› Verified 5 days ago
| Entity Name | Greenville Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568532513 PECOS PAC ID: 8123938131 Enrollment ID: O20031212000723 |
News Archive
Research from the University of Southampton has shown that young adults, who are more outgoing or more emotionally stable, are happier in later life than their more introverted or less emotionally stable peers.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There is no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Debusk, DO 239 Chippewa Dr, Bowling Green, KY 42103-1376 Ph: () - | Abigail Debusk, DO 825 2nd Ave, Suite C2, Bowling Green, KY 42101-1786 Ph: (270) 780-2750 |
News Archive
Research from the University of Southampton has shown that young adults, who are more outgoing or more emotionally stable, are happier in later life than their more introverted or less emotionally stable peers.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There is no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV.
› Verified 5 days ago
Dr. William C. Kemp, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1777 Ashley Cir, Bowling Green, KY 42104 Phone: 270-781-4090 Fax: 270-842-3133 | |
Dr. Chase Andrew Beliles, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 990 Wilkinson Trce, Bowling Green, KY 42103 Phone: 270-781-4043 Fax: 270-781-4196 | |
Dr. Lindsey Whiteman Brooks, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2724 Nashville Rd, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-393-2738 | |
Dr. Craig Losekamp, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-783-3330 Fax: 270-936-6030 | |
Dr. Medhat N. Grace, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1225 Fairway St, Bowling Green, KY 42103 Phone: 270-781-3910 Fax: 270-842-7177 | |
Dr. David C Napier, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2724 Nashville Rd, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-936-6026 | |
Dr. Emily Cecil, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 2nd Ave Ste B3, Bowling Green, KY 42101 Phone: 270-901-0629 Fax: 270-901-0892 |